Dr. Reddy’s Laboratories Ltd ADR (RDY)

53.52
+0.27(+0.51%)
  • Volume:
    38,026
  • Day's Range:
    53.16 - 53.54
  • 52 wk Range:
    47.88 - 65.86

RDY Overview

Prev. Close
53.25
Day's Range
53.16-53.54
Revenue
2.29B
Open
53.16
52 wk Range
47.88-65.86
EPS
186.45
Volume
38,026
Market Cap
8.79B
Dividend (Yield)
0.3171
(0.60%)
Average Volume (3m)
237,985
P/E Ratio
23.40
Beta
0.22
1-Year Change
-11.72%
Shares Outstanding
166,051,752
Next Earnings Date
02 Feb 2023
What is your sentiment on Dr. Reddy’s Labs ADR?
or
Vote to see community's results!

Dr. Reddy’s Laboratories Ltd ADR News

Dr. Reddy’s Laboratories Ltd ADR Analysis

Dr. Reddy’s Laboratories Ltd ADR Company Profile

Dr. Reddy’s Laboratories Ltd ADR Company Profile

Employees
24795

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Read More

Analyst Price Target

Average62.37 (+16.57% Upside)
High67.00
Low57.00
Price53.50
No. of Analysts3
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuySellStrong SellSell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell
  • best time let's rock
    1
    • Very soon it will be in 3 digits ie 100+ so keep accumulating
      1
      • buy it will fly
        2
        • with in 15 days it will touch 45
          0
          • strongly recommend only sell
            0
            • buy only buy cross 53.50 today
              0
              • buy it will cross 51.71 today
                0
                • go for buying it will definitely in positive zone green zone
                  0
                  • dr reddy enter in bull mkt now. only buy
                    0
                    • target 36
                      3